Dr Phil Reilly on newborn screening: past, present and future

October 13, 2022 Bullet Article
Phil ReillyPhil Reilly
Will GreeneWill Greene
Rare Diseases C-Suite Perspectives Leaders In Conversation Newborn Screening
Share this:
Copy link
Dr Phil Reilly on newborn screening: past, present and future

Dr Phil Reilly is a physician, clinical geneticist, biotech entrepreneur, venture capitalist and author with deep experience in rare disease diagnostics, including newborn screening (NBS). In this Q&A with Will Greene, Healthcare Engagement Manager and Project Strongbow Co-Lead at Roche Diagnostics Asia Pacific, we learn more about the history and future of newborn screening technologies in the United States and around the world.

Share this:
Copy link

More on same topic

Select a related post from the options below.

Emerging haemophilia therapies highlight a need for quality diagnostics

Newborn screening in Taiwan: Q&A with Dr Yin-Hsiu (Nancy) Chien

Recommended topics

SequencingRED 2020Rare Diseases
Next Read
Management
ā€¢ Articles
Creating a healthier Singapore with digital solutions: Q&A with Glenn Neo
How Awanui Group drives diagnostic excellence in New Zealand: Q&A with Anoop Singh (Part 1)
Management
ā€¢ Articles
Awanui Group’s quest to improve lab diagnostics in New Zealand: Q&A with Anoop Singh (Part 1)
ā€˜Real world evidenceā€™ and clinical labs: a brief introduction
Operations
ā€¢ Articles
ā€˜Real world evidenceā€™ and clinical labs: a brief introduction
ā€˜Chasing the Invisibleā€™ and the future of the clinical lab: Q&A with Dr Thomas Grogan (Part 3)
Operations
ā€¢ Articles
Chasing the Invisible and the future of the clinical lab: Q&A with Dr Thomas Grogan (Part 3)
Scroll to Top